277 related articles for article (PubMed ID: 38672458)
1. The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.
Havrylyuk D; Heidary DK; Glazer EC
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672458
[TBL] [Abstract][Full Text] [Related]
2. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
Rendic SP; Peter Guengerich F
Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
[TBL] [Abstract][Full Text] [Related]
3. Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
Zhao L; Sun N; Tian L; Zhao S; Sun B; Sun Y; Zhao D
Bioorg Med Chem Lett; 2019 Aug; 29(16):2016-2024. PubMed ID: 31257085
[TBL] [Abstract][Full Text] [Related]
4. The current understanding of the interactions between nanoparticles and cytochrome P450 enzymes - a literature-based review.
Pan Y; Ong CE; Pung YF; Chieng JY
Xenobiotica; 2019 Jul; 49(7):863-876. PubMed ID: 30028220
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking as a Promising Predictive Model for Silver Nanoparticle-Mediated Inhibition of Cytochrome P450 Enzymes.
Wasukan N; Kuno M; Maniratanachote R
J Chem Inf Model; 2019 Dec; 59(12):5126-5134. PubMed ID: 31714078
[TBL] [Abstract][Full Text] [Related]
7. Inhibition and induction of CYP enzymes in humans: an update.
Hakkola J; Hukkanen J; Turpeinen M; Pelkonen O
Arch Toxicol; 2020 Nov; 94(11):3671-3722. PubMed ID: 33111191
[TBL] [Abstract][Full Text] [Related]
8. CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes.
Plonka W; Stork C; Šícho M; Kirchmair J
Bioorg Med Chem; 2021 Sep; 46():116388. PubMed ID: 34488021
[TBL] [Abstract][Full Text] [Related]
9. Structure-based ligand design to overcome CYP inhibition in drug discovery projects.
Brändén G; Sjögren T; Schnecke V; Xue Y
Drug Discov Today; 2014 Jul; 19(7):905-11. PubMed ID: 24642031
[TBL] [Abstract][Full Text] [Related]
10. Selective Targeting of Heme Protein in Cytochrome P450 and Nitric Oxide Synthase by Diphenyleneiodonium.
Szilagyi JT; Mishin V; Heck DE; Jan YH; Aleksunes LM; Richardson JR; Heindel ND; Laskin DL; Laskin JD
Toxicol Sci; 2016 May; 151(1):150-9. PubMed ID: 26880746
[TBL] [Abstract][Full Text] [Related]
11. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
12. Computational prediction of cytochrome P450 inhibition and induction.
Kato H
Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468
[TBL] [Abstract][Full Text] [Related]
13. Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design.
Rekka EA; Kourounakis PN; Pantelidou M
Curr Top Med Chem; 2019; 19(4):276-291. PubMed ID: 30706817
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
15. Curcumin, Piperine, and Capsaicin: A Comparative Study of Spice-Mediated Inhibition of Human Cytochrome P450 Isozyme Activities.
Shamsi S; Tran H; Tan RS; Tan ZJ; Lim LY
Drug Metab Dispos; 2017 Jan; 45(1):49-55. PubMed ID: 27821437
[TBL] [Abstract][Full Text] [Related]
16. Inhibiton of cytochrome P450 isoenzymes and P-gp activity by multiple extracts of Huang-Lian-Jie-Du decoction.
Wang Y; Jiang YM; Wang YT; Kang JW; Yu T; Zhao HY; Bian BL; Huang M; Bi HC
J Ethnopharmacol; 2014 Oct; 156():175-81. PubMed ID: 25219605
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain.
Stocco MR; Tyndale RF
Adv Pharmacol; 2022; 95():73-106. PubMed ID: 35953164
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage.
Zamora A; Denning CA; Heidary DK; Wachter E; Nease LA; Ruiz J; Glazer EC
Dalton Trans; 2017 Feb; 46(7):2165-2173. PubMed ID: 28121322
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into understudied human cytochrome P450 enzymes.
Machalz D; Pach S; Bermudez M; Bureik M; Wolber G
Drug Discov Today; 2021 Oct; 26(10):2456-2464. PubMed ID: 34161845
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
